Why Lilly is betting on peripheral pain biology with the 4E Therapeutics acquisition
Find out how Lilly’s 4E Therapeutics deal could advance non-opioid chronic pain drugs and what risks remain.
Pharma & Biotech
Medical Devices & Diagnostics
Medtronic’s SPR Therapeutics deal signals a sharper move into earlier chronic pain intervention
Chronic pain care needs non-opioid options. Medtronic’s SPR Therapeutics deal tests whether temporary PNS can scale beyond niche adoption.
Pharma & Biotech
Is BRC Therapeutics opening a new regulatory lane for cannabinoid-based CRPS therapies?
CRPS has no approved U.S. therapy. BRC-002 now has an FDA path, but proof of safety, efficacy, and dosing discipline still lies ahead.
Pharma & Biotech
How Sparian Biosciences’ Phase 1 launch of SBS-147 could reshape the non-opioid pain treatment landscape
Discover how Sparian Biosciences’ SBS-147 Phase 1 launch could change the race for safer non-opioid pain treatments. Read the full analysis.
Medical Devices & Diagnostics
Nalu Medical’s wearable-powered PNS shows strong 24-month durability in COMFORT RCT
Nalu’s PNS system shows 85% responder rate at 24 months. Find out what this long-term data means for neuromodulation’s future.
Medical Devices & Diagnostics
What BIOTRONIK’s partnership with Soin Neuroscience reveals about the future of neuromodulation
Soin Neuroscience and BIOTRONIK Neuro have announced a research collaboration focused on evaluating novel waveform technology and adaptive spinal cord stimulation programming aimed at enhancing chronic pain treatment outcomes. The partnership integrates proprietary signal tuning algorithms from Soin Neuroscience with the programmable Prospera SCS system developed by BIOTRONIK Neuro, reinforcing a broader industry shift toward